Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
27.60
+0.34 (+1.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma Plc Cl A
< Previous
1
2
3
4
5
6
Next >
Looking Into Royalty Pharma's Recent Short Interest
April 04, 2024
Via
Benzinga
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
March 29, 2024
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock with good fundamentals.
Via
Chartmill
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
March 27, 2024
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
Via
InvestorPlace
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
February 29, 2024
When you look at ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
February 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Royalty Pharma's Earnings: A Preview
February 14, 2024
Via
Benzinga
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
December 26, 2023
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued.
Via
Chartmill
NASDAQ:RPRX: good value for what you're paying.
November 14, 2023
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued.
Via
Chartmill
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
February 16, 2024
Analysts are quite bullish about these beaten-down stocks.
Via
The Motley Fool
Royalty Pharma Reports Q4 and Full Year 2023 Results
February 15, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
February 08, 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.
Via
InvestorPlace
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 08, 2024
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals.
Via
Chartmill
Royalty Pharma's Earnings Outlook
November 07, 2023
Via
Benzinga
How Risky Is Royalty Pharma’s Dividend?
February 07, 2024
Royalty Pharma just announced a 5% dividend increase, its fourth raise in a row. It has boosted the dividend every year since it began paying one in 2020. The new $0.21 per share quarterly dividend...
Via
Talk Markets
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
January 30, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Top Stocks That Just Increased Their Dividends
January 23, 2024
There are several reasons why investors tend to favor stocks that have had a dividend increase.
Via
Talk Markets
Royalty Pharma Announces Dividend Increase
January 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
NASDAQ:RPRX appears to be flying under the radar despite its strong fundamentals.
January 17, 2024
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals.
Via
Chartmill
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
December 05, 2023
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
November 27, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
November 13, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
November 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Royalty Pharma Reports Third Quarter 2023 Results
November 08, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Why PTC Therapeutics Soared 15% Higher Today
October 19, 2023
The company scored a $1 billion upfront payment for expanding a commercial partnership.
Via
The Motley Fool
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
October 19, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2023 Dividend
October 16, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
October 11, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
September 21, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.